Arbutus Biopharma Corp
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 1 and phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expre… Read more
Arbutus Biopharma Corp (ABUS) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.075x
Based on the latest financial reports, Arbutus Biopharma Corp (ABUS) has a cash flow conversion efficiency ratio of -0.075x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.82 Million) by net assets ($77.40 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Arbutus Biopharma Corp - Cash Flow Conversion Efficiency Trend (1998–2024)
This chart illustrates how Arbutus Biopharma Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Arbutus Biopharma Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Arbutus Biopharma Corp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
FirstSun Capital Bancorp Common Stock
OTCQX:FSUN
|
0.044x |
|
Medincell SA
PA:MEDCL
|
0.465x |
|
Shenzhen Lihexing Co. Ltd.
SHE:301013
|
-0.030x |
|
Shaanxi Heimao Coking Co Ltd
SHG:601015
|
0.086x |
|
Shandong Jincheng Pharmaceutical and Chemical Co Ltd
SHE:300233
|
0.021x |
|
Cosonic Intelligent Tech Co Ltd
SHE:300793
|
-0.026x |
|
Sumitomo Chemical India Limited
NSE:SUMICHEM
|
0.136x |
|
Vitesse Energy Inc
NYSE:VTS
|
0.076x |
Annual Cash Flow Conversion Efficiency for Arbutus Biopharma Corp (1998–2024)
The table below shows the annual cash flow conversion efficiency of Arbutus Biopharma Corp from 1998 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $97.37 Million | $-64.85 Million | -0.666x | +17.83% |
| 2023-12-31 | $106.02 Million | $-85.94 Million | -0.811x | -213.75% |
| 2022-12-31 | $136.85 Million | $-35.36 Million | -0.258x | +35.18% |
| 2021-12-31 | $169.44 Million | $-67.53 Million | -0.399x | +21.00% |
| 2020-12-31 | $101.97 Million | $-51.44 Million | -0.504x | +48.32% |
| 2019-12-31 | $72.74 Million | $-71.01 Million | -0.976x | -187.85% |
| 2018-12-31 | $200.23 Million | $-67.90 Million | -0.339x | -27.34% |
| 2017-12-31 | $182.50 Million | $-48.60 Million | -0.266x | +6.61% |
| 2016-12-31 | $203.00 Million | $-57.88 Million | -0.285x | -185.06% |
| 2015-12-31 | $547.68 Million | $-54.78 Million | -0.100x | +29.13% |
| 2014-12-31 | $88.00 Million | $-12.42 Million | -0.141x | -23.99% |
| 2013-12-31 | $59.19 Million | $-6.74 Million | -0.114x | -114.00% |
| 2012-12-31 | $40.92 Million | $33.27 Million | 0.813x | +156.28% |
| 2011-12-31 | $5.21 Million | $-7.52 Million | -1.445x | -37.84% |
| 2010-12-31 | $10.73 Million | $-11.25 Million | -1.048x | -608.93% |
| 2009-12-31 | $35.44 Million | $-5.24 Million | -0.148x | +33.28% |
| 2008-12-31 | $38.29 Million | $-8.48 Million | -0.222x | -49.67% |
| 2007-12-31 | $18.37 Million | $-2.72 Million | -0.148x | +99.12% |
| 2006-12-31 | $155.53K | $-2.62 Million | -16.866x | -2240.30% |
| 2005-12-31 | $-18.49 Million | $-14.57 Million | 0.788x | -17.14% |
| 2004-12-31 | $-10.50 Million | $-9.98 Million | 0.951x | +253.00% |
| 2003-12-31 | $43.38 Million | $-26.96 Million | -0.622x | -55.24% |
| 2002-12-31 | $45.35 Million | $-18.16 Million | -0.400x | -146.08% |
| 2001-12-31 | $61.49 Million | $-10.00 Million | -0.163x | +41.51% |
| 2000-12-31 | $30.03 Million | $-8.35 Million | -0.278x | -9.37% |
| 1999-12-31 | $26.88 Million | $-6.84 Million | -0.254x | +52.39% |
| 1998-12-31 | $14.43 Million | $-7.71 Million | -0.534x | -- |